Jump to content

  • Log in with Facebook Log in with Twitter Log In with Google Sign In
  • Create Account

Support, help, advice & information for Multiple Sclerosis. Ask questions & share experiences with people affected by MS.

DMF kills Memory B cells

  • You cannot start a new topic
  • Please log in to reply
No replies to this topic

RSS News

RSS News

    RSS News Feed Reader

  • Staff
  • 5,611 posts
  • Joined: 25-May 08
    Member: 792
  • Gender:Not Telling

Current mood: None chosen
Smith MD, Martin KA, Calabresi PA, Bhargava P.Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. Ann Clin Transl Neurol. 2017 Apr 17;4(5):351-355.

We evaluated the effect of dimethyl fumarate (DMF) treatment on B-cell memory and cytokine production in 18 patients with relapsing remitting multiple sclerosis (RRMS) using peripheral blood mononuclear cells obtained prior to and at 6 months post-DMF initiation. We noted a decline in the absolute B-cell number with DMF treatment, with a preferential depletion of memory B cells and a concurrent increase in naïve B cells. We noted significant reductions in GM-CSF, TNF-α, and IL-6 producing B cells with DMF treatment. These effects on the B-cell compartment may underlie the beneficial effects of DMF in RRMS.

Looks like we have hit on "flavour of the year" and I'm not sure how to deal with conforming to the norm:-(. This is that the agents that seem to be affecting MS the most are the memory B cells. 

I'm sure you are getting bored with this endless stream of supportive data. However are the T cellers interested?...Probably not.

However I have said it is the absolute number that is important , if the memory cell population within the CD19 population does down, the other CD19 populations go up as a percentage. But if you rely on percentages you can look a real idiot when you realise the absolute number of cells tells you something else. But based on what we published, perhaps the data in this paper says why you can do better with DMF.

So have a read of our paper and look at figure 4.

This cost me a few hundred quid to pay for the copyright, but I did this so that you don't have to look through a few papers. 

What you can see is the highly active agents keep the memory cells as a low percentage of the CD19 positive population. But let's look at the results from this current paper (above) and you can see  what may the issue. For the highly active agents, they deplete memory B cells below 20% of the CD19%  population. 

You can see that a few people treated with DMF don't make that mark. 

Is this a reason for failure? As you can see, I am pressing a few buttons so that the companies with the data will prove me wrong. 

View the full article

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users

The MS People Forum is not responsible for advice or information supplied by members. We suggest you seek medical advice before trying anything.
Messages posted within the Forum express only the views of the author of the message and do not necessarily reflect the views of MS-People.com.
MS-People.com nor any person or entity associated with them will be held responsible for the contents, accuracy, completeness or validity of any information posted on the site.